MENU

zac haughn

Results that match your search are below

Filters

Content Type

Issue Year


Sort By:

Relevance Date

Belsomra: A First Look

Sleep medicine's newest addition has a novel mechanism and an undecided future.

Zac Haughn, Senior Associate Editor

Out With the Old, In With (Mostly) the Old

Recent changes to the acute migraine guidelines were more subtle than sweeping.

Zac Haughn, Senior Associate Editor

In The Pipeline: Don't Bother: Investigational Compound Reduces AD-related Agitation

Alzheimer's patients who experience agitation saw a nearly 50 percent decline in their symptoms after treatment with an investigational therapy.

Zac Haughn, Senior Associate Editor

In the Pipeline: An Infusion of Possibilities: rHIgM22

An intravenous infusion study looks at rHIgM22 as a potential remyelinating agent.

Zac Haughn, Senior Associate Editor

In The Pipeline: Crossing the Blood-Brain Barrier to Fight Tumors

Zac Haughn, Senior Associate Editor

Special Report: A Touching Movement

A quadriplegic man moved neuromodulation a step forward.

Zac Haughn, Senior Associate Editor

New Utensil Gives Patients a Lift

A specially engineered spoon can help patients deal with tremors.

Zac Haughn, Senior Associate Editor

Knocking Out PD Symptoms?

Exercise is crucial for patients with Parkinson's. One program wants to give them a fighting chance.

Zac Haughn, Senior Associate Editor

Movement Disorders Focus: Thinking Outside the Brain

Alpha-synuclein pathology linked to Parkinson's is being detected outside the brain, in places like the salivary glands, retina and colon.

Zac Haughn, Senior Associate Editor

Features

Health Law Update: What's Next?

The Independent Payment Advisory Board was tasked with achieving savings in Medicare but has now been gutted by Congress and may never become operational.

Zac Haughn, Senior Associate Editor

Cover Focus

A Closer Look at Parkinson's Therapies

An update by Practical Neurology

Zac Haughn, Senior Associate Editor

Features

Decreasing Progression, Increasing Function

A small Phase I ALS study is getting big results with stem cell treatment.

Zac Haughn, Senior Associate Editor

Patients Prefer Oral Therapy Over Injections

Phase IV data for fingolimod show high levels of patient satisfaction with oral therapy over injectables.

Zac Haughn, Senior Associate Editor

Departments

In the Pipeline: Parkinson's Management: “Now Breath In…”

An inhalable form of levodopa aims to assist during “off” periods

Zac Haughn, Senior Associate Editor

Epilepsy: Now and in the Future

New drugs continue to offer hope to patients, as research seeks other ways to optimize care.

Zac Haughn, Senior Associate Editor

Departments

Bionic Breakout: Robotic-Assisted Therapy Is Evolving

Robotic-assisted therapy has made significant strides in the past 15 years. Will it overtake conventional physical therapy?

Zac Haughn, Senior Associate Editor

The Epilepsy Pipeline

In any disorder, the pipeline is the lifeblood of patients' and physicians' hopes for more promising care and better results. And epilepsy's pipeline has several drugs worth keeping an eye on.

Zac Haughn, Senior Associate Editor

The Brain Activity Map: Answers for Alzheimer's and More?

An ambitious new research goal seeks to better understand how the brain works. Will the project succeed, and what will it actually show?

Zac Haughn, Senior Associate Editor

The Bright Lights: Will New AD Therapy Really Shine?

Investigational drug studies are being hyped with promising results in dementia. Can the therapies live up to lofty expectations?

Zac Haughn, Senior Associate Editor

The Other Kind of Kicking: RLS in Pregnancy

Women are much more likely to develop RLS after becoming pregnant. Here, specialists discuss how to manage the condition

Zac Haughn, Senior Associate Editor

Show More

This Month's Issue
Hyperkinetic Movement Disorders

Zehra Farzal, MD; Guillaume Lamotte MD, MSc; and Laxman B. Bahroo, DO

Parkinson’s Disease Treatment Update

Zehra Farzal, MD; Guillaume Lamotte MD, MSc; and Laxman B. Bahroo, DO